The relationship between EGFR-TKI resistance and PD-L1 expression in the treatment of lung cancer / 中国肿瘤生物治疗杂志
Chinese Journal of Cancer Biotherapy
;
(6): 171-175, 2021.
Artigo
em Chinês
| WPRIM
| ID: wpr-875868
ABSTRACT
@#[ 摘 要 ] 表皮生长因子受体酪氨酸激酶抑制剂(epidermal growth factor receptor tyrosine kinase inhibitor,EGFR-TKI)的上市, 使治疗EGFR 突变的晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)患者的客观有效率达到79%,取得了显著的抗肿瘤 治疗效果。然而,耐药是EGFR-TKIs 治疗的瓶颈,对耐药机制的研究以及耐药后的治疗策略,成为肺癌治疗的难点和热点问 题。随着免疫治疗的兴起,越来越多的证据发现,PD-L1 不仅与EGFR 基因突变之间存在调节关系,而且PD-L1 表达和EGFR-TKIs 耐药也显示出新的相关性。探究PD-L1 表达与EGFR-TKIs 耐药之间的关系对寻找EGFR-TKIs 耐药后治疗策略具有重要意义。
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Idioma:
Chinês
Revista:
Chinese Journal of Cancer Biotherapy
Ano de publicação:
2021
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS